1 June 2018 - The June 2018 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The June issue of the Schedule includes a number of new/revised listings:

• Cabozantinib maleate (Cabometyx) - new medicine
  
• Dulaglutide (Trulicity) - new medicine
  
• Fluticasone furoate with vilanterol trifenatate and umeclidinium bromide (Trelegy Ellipta) - new combination product
  
• Golimumab (Simponi) - new indication
  
• Nusinersen sodium (Spinraza) - new gene therapy
  

Read Summary of Changes